All In Biotech

Drug Trial Radar · NCT07304011

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

A Phase 2 Study of Olutasidenib in Combination With Azacitidine Followed by Olutasidenib Maintenance After Venetoclax Plus a Hypomethylating Agent Regimen (HMA-VEN) for IDH1-Mutated Acute Myeloid Leukemia (AML)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Dec 17, 2025

Primary completion

Dec 1, 2027

Study completion Dec 1, 2029

Sponsor

Lead sponsor
University of California, DavisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Dec 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well giving olutasidenib with azacitidine, followed by olutasidenib maintenance, works in treating patients with IDH1-mutated acute myeloid leukemia (AML) who have received prior treatment with venetoclax plus a hypomethylating agent (HMA-Ven). Olutasidenib and azacitidine may inhibit the growth of cancer cells by blocking certain enzymes required for cell growth. Maintenance therapy can help prevent or delay cancer from coming back. Olutasidenib with azacitidine followed by olutasidenib maintenance may be effective in treating patients with IDH1-mutated AML who have received prior HMA-Ven.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • AzacitidineDrug

    Given IV or SC

  • OlutasidenibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment failureTime frame: At 12 months from complete response (CR)/complete remission with incomplete count recovery (CRi)
  2. Median time to treatment failureTime frame: From CR/CRi through death due to AML, relapse, or treatment discontinuation due to adverse event, assessed up to 4 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Jonsson Comprehensive Cancer Center

    Los Angeles, California · Not yet recruiting

  • UCI Health Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.